The house that Zantac built

Glaxo pins its hopes on a new hi-tech research centre in Stevenage

THE footbridge across the peaceful artificial lake in Stevenage seems far away from the bitter takeover battle between drugs companies Glaxo and Wellcome. But when the Medicines Research Centre opens in April, it could be accommodating scientistsfrom both companies, united in a quest for the world's next super drug. Their success or failure will determine the future of Glaxo. Known as Sykes's Folly, after Sir Richard, Sykes, the chairman of Glaxo, or The House that Zantac Built, after the company's best-selling ulcer drug, the £700m centre is impressive. Teams of six will work in each of the gleaming labs, doing their experiments in sealed fume cupboards rather than on the benches, which will instead be crowded with electronic instruments. One wing contains fermentation vats for growing microbes, another has a pilot plant for increasing production from laboratory quantitiesto commercial levels.

The problems to be solved behind the concrete and glass facade are not merely academic. Glaxo is heavily dependent on Zantac, some analysts say too heavily. The world's best-selling drug makes up 40 per cent of the company's revenues, and it is already beginning to slip, six years before its patents start to run out. The company aims to triple the number of replacement drugs it brings to market while its revenues dwindle and research costs (£900m this year) inflate.

Sir Richard has taken two steps towards solving Glaxo's dilemma, starting with the high-profile £9.2bn bid for Wellcome. Combined, the two companies would have more weight in what has become a buyers' market. Savings from cutting duplicated overheads will also help to fund more research. And Glaxo will be able to capitalise on any likely drug candidates now in Wellcome's experimental pipeline.

The smaller, but potentially more significant step is the agreed takeover of Affymax in Palo Alto, California, for up to $550m (£348m). "Affymax is about the future,'' Sir Richard said at the weekend. "There has to be a constant flow of new medicines. Wecan't do that with traditional techniques that produce one new molecule a week.'' Until recently, pharmaceutical companies discovered new drugs, usually by sifting through naturally occurring organic chemicals. Now they want to create medicines from scratch. The first step is to make a molecule that will bind with its target, be it a cell membrane, an enzyme or the shell of a virus. Sometimes only one in a million will do this, so lots of molecules have to be built up quickly. Affymax does just that.

The US company was founded in 1989 by Dr Al Zaffaroni, the father of the oral contraceptive, who is now in his seventies. It is regarded as the leading player in a new field called combinatorial chemistry. One of its key techniques, borrowed from the computer industry, is a method of building hundreds of thousands of unique molecules from scratch on a silicon chip in just a few hours. These can then be quickly tested to see which ones will bind with the desired target.

Once a molecule that works is found by this method, thousands of variations can be tested to see which work best.

A handful will then be sent to Stevenage, Hertfordshire, for testing. The result, argues Sir Richard, will be drugs that are more accurate, more therapeutic and have fewer side-effects.

Start your day with The Independent, sign up for daily news emails
ebooksAn introduction to the ground rules of British democracy
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: Talent Acquisition Consultant

£22500 - £27000 per annum + OTE £45K: SThree: Since our inception in 1986, STh...

Recruitment Genius: Experienced Financial Advisers and Paraplanners

Negotiable: Recruitment Genius: This extremely successful and well-established...

Guru Careers: FX Trader / Risk Manager

Competitive with monthly bonus: Guru Careers: We are seeking an experienced FX...

Guru Careers: Investment Writer / Stock Picker

Competitive (Freelance) : Guru Careers: An Investment Writer / Stock Picker is...

Day In a Page

How to stop an asteroid hitting Earth: Would people co-operate to face down a global peril?

How to stop an asteroid hitting Earth

Would people cooperate to face a global peril?
Just one day to find €1.6bn: Greece edges nearer euro exit

One day to find €1.6bn

Greece is edging inexorably towards an exit from the euro
New 'Iron Man' augmented reality technology could help surgeons and firefighters, say scientists

'Iron Man' augmented reality technology could become reality

Holographic projections would provide extra information on objects in a person's visual field in real time
Sugary drinks 'are killing 184,000 adults around the world every year'

Sugary drinks are killing 184,000 adults around the world every year

The drinks that should be eliminated from people's diets
Pride of Place: Historians map out untold LGBT histories of locations throughout UK

Historians map out untold LGBT histories

Public are being asked to help improve the map
Lionel, Patti, Burt and The Who rock Glasto

Lionel, Patti, Burt and The Who rock Glasto

This was the year of 24-carat Golden Oldies
Paris Fashion Week

Paris Fashion Week

Thom Browne's scarecrows offer a rare beacon in commercial offerings
A year of the caliphate:

Isis, a year of the caliphate

Who can defeat the so-called 'Islamic State' – and how?
Marks and Spencer: Can a new team of designers put the spark back into the high-street brand?

Marks and Spencer

Can a new team of designers put the spark back into the high-street brand?
'We haven't invaded France': Italy's Prime Minister 'reclaims' Europe's highest peak

'We haven't invaded France'

Italy's Prime Minister 'reclaims' Europe's highest peak
Isis in Kobani: Why we ignore the worst of the massacres

Why do we ignore the worst of the massacres?

The West’s determination not to offend its Sunni allies helps Isis and puts us all at risk, says Patrick Cockburn
7/7 bombings 10 years on: Four emergency workers who saved lives recall the shocking day that 52 people were killed

Remembering 7/7 ten years on

Four emergency workers recall their memories of that day – and reveal how it's affected them ever since
Humans: Are the scientists developing robots in danger of replicating the hit Channel 4 drama?

They’re here to help

We want robots to do our drudge work, and to look enough like us for comfort. But are the scientists developing artificial intelligence in danger of replicating the TV drama Humans?
Time to lay these myths about the Deep South to rest

Time to lay these myths about the Deep South to rest

'Heritage' is a loaded word in the Dixie, but the Charleston killings show how dangerous it is to cling to a deadly past, says Rupert Cornwell
What exactly does 'one' mean? Court of Appeal passes judgement on thorny mathematical issue

What exactly does 'one' mean?

Court of Appeal passes judgement on thorny mathematical issue